Prehliadač alebo jeho nastavenia nie sú podporované.

Praktik.ai používa moderné webové technológie kvôli bezpečnosti, rýchlosti a spoľahlivému prihlasovaniu. Tento prehliadač ich nepodporuje alebo blokuje JavaScript, preto sa aplikácia nemusí správne načítať.

Aktualizujte prosím Chrome, Edge, Firefox alebo Safari na najnovšiu verziu a stránku potom obnovte.

Ak používate Windows 7, Windows 8 alebo Windows 8.1, Chrome a Edge už nemusia ponúkať novú verziu. V takom prípade použite novšie zariadenie alebo kontaktujte podporu Praktik.ai.

Prohlížeč nebo jeho nastavení nejsou podporované.

Praktik.ai používá moderní webové technologie kvůli bezpečnosti, rychlosti a spolehlivému přihlašování. Tento prohlížeč je nepodporuje nebo blokuje JavaScript, proto se aplikace nemusí správně načíst.

Aktualizujte prosím Chrome, Edge, Firefox nebo Safari na nejnovější verzi a stránku potom obnovte.

Pokud používáte Windows 7, Windows 8 nebo Windows 8.1, Chrome a Edge už nemusí nabízet novou verzi. V takovém případě použijte novější zařízení nebo kontaktujte podporu Praktik.ai.

Your browser or its settings are not supported.

Praktik.ai uses modern web technologies for security, speed, and reliable sign-in. This browser does not support them, or JavaScript is blocked, so the app may not load correctly.

Please update Chrome, Edge, Firefox, or Safari to the latest version and then reload this page.

If you use Windows 7, Windows 8, or Windows 8.1, Chrome and Edge may no longer offer a newer version. In that case, use a newer device or contact Praktik.ai support.

Effective COMMISSION DECISION of 10 February 2011 authorising a laboratory in the Republic of Korea to carry out serological tests to monitor the effectiveness of rabies vaccines (notified under document C(2011) 656) (Text with EEA relevance) (2011/91/EU)

Rozhodnutie č. 91/2011

Text language

Important dates

Declared: 10. februára 2011
Approved: 10. februára 2011
Effective from: 11. februára 2011

Documents and links

COMMISSION DECISION

of 10 February 2011

authorising a laboratory in the Republic of Korea to carry out serological tests to monitor the effectiveness of rabies vaccines

(notified under document C(2011) 656)

(Text with EEA relevance)

(2011/91/EU)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Decision 2000/258/EC of 20 March 2000 designating a specific institute responsible for establishing the criteria necessary for standardising the serological tests to monitor the effectiveness of rabies vaccines (1), and in particular Article 3(2) thereof,

Whereas:

(1)

Decision 2000/258/EC designates the laboratory of the Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES) in Nancy (previously Agence française de sécurité sanitaire des aliments (AFSSA)) as the specific institute responsible for establishing the criteria necessary for standardising the serological tests to monitor the effectiveness of rabies vaccines. That Decision also lays down the duties of that laboratory.

(2)

In particular, ANSES, Nancy, is to appraise the laboratories in Member States and third countries in order to decide whether to authorise the laboratories to carry out serological tests to monitor the effectiveness of rabies vaccines.

(3)

The competent authority of South Korea has submitted an application for approval of a laboratory in that third country to perform such serological tests.

(4)

ANSES, Nancy has carried out an appraisal of that laboratory and provided the Commission with a favourable report of that appraisal on 6 September 2010.

(5)

That laboratory should therefore be authorised to carry out serological tests to monitor the effectiveness of rabies vaccines in dogs, cats and ferrets.

(6)

The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,

HAS ADOPTED THIS DECISION:

Article 1

In accordance with Article 3(2) of Decision 2000/258/EC, the following laboratory is authorised to perform the serological tests to monitor the effectiveness of rabies vaccines in dogs, cats and ferrets:

Komipharm International Co. Ltd

1236-6 Jeoungwang-dong

420-450 Siheung-si, Gyeonggi-do

South Korea

Article 2

This Decision shall apply from 1 March 2011.

Article 3

This Decision is addressed to the Member States.

Done at Brussels, 10 February 2011.

For the Commission

John DALLI

Member of the Commission

Poznámky